Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time
MONMOUTH JUNCTION, New Jersey, November 15, 2021/PRNewswire/ - CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the use of blood purification to treat life-threatening diseases in intensive care units and heart surgery. Announced its participation in two upcoming investor meetings.
CytoSorbents will attend the Canaccord Genuity Virtual Medical Technology, Diagnosis and Digital Health and Service Forum on Thursday, November 18, 2021. Dr. Phillip Chan, CEO of CytoSorbents, will briefly introduce the company's operations and prospects through the following webcast link at 11:00 am Eastern Time. The company's management will also meet with investors throughout the day.
Dr. Chen will also attend the 2021 Jefferies London Healthcare Conference. The presentation will begin on Thursday, November 18, 2021, at 3 a.m. Eastern Time, and will be available for on-demand viewing via the webcast link below. The management will also hold an investor meeting on Friday, November 19, 2021.
The archive records of CytoSorbents’ speeches at the two investor meetings will be available in the Investor Relations section of the company’s website Events & Presentations-Cytosorbents, valid for 30 days.
About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the use of blood purification to treat life-threatening diseases in intensive care and cardiac surgery. Its flagship product, CytoSorb®, has been approved in the European Union and is sold in more than 70 countries/regions as an in vitro cytokine adsorbent, aiming to reduce the "cytokine storm" or "cytokine release syndrome" that occurs in common critical diseases. The disease can result in massive inflammation, organ failure, and patient death. In these cases, the risk of death may be very high, but there are few effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that may cause post-operative complications including multiple organ failure. So far, more than 152,000 CytoSorb devices have been used cumulatively. CytoSorb was originally introduced into the European Union under the CE mark and is a cytokine adsorbent of the same kind. Obtained additional CE-Mark label extensions for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, as well as ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received emergency use authorization from the US FDA and can be used for adults with severe COVID-19 who are about to develop or have confirmed respiratory failure. The DrugSorb™-ATR antithrombotic removal system is based on the same polymer technology as CytoSorb, and has also received FDA breakthrough designation to remove ticagrelor, and FDA breakthrough designation for apixaban to remove direct oral anticoagulant (DOAC) And rivaroxaban, used in cardiopulmonary bypass during emergency cardiothoracic surgery. The company is launching two key FDA-approved trials to support the US marketing approval of DrugSorb-ATR. The first is a STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized controlled trial with 120 patients and 20 centers to evaluate the intraoperative use of DrugSorb-ATR to reduce the circumference of patients undergoing ticagrelor undergoing cardiothoracic surgery. Ability to risk bleeding during surgery. The second is a STAR-D (safe and timely antithrombotic removal-direct oral anticoagulant) randomized controlled trial in 120 patients and 25 centers to evaluate the intraoperative use of DrugSorb-ATR to reduce the circumference of patients undergoing direct oral cardiothoracic surgery. Anticoagulants at risk of bleeding during surgery include apixaban and rivaroxaban.
CytoSorbents' purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances in blood and other body fluids through pore capture and surface adsorption. Its technology has received more than $39.5 million in non-dilutable grants, contracts and other funding from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Heart, Lung, and Blood Center (NHLBI), US Army, US Air Force, US Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), etc. The company has many marketed products and products under development based on this unique blood purification technology, protected by a number of issued patents and registered trademarks in the United States and internationally, and a number of patent applications are pending, including ECOS-300CY®, CytoSorb-XL ™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, Kontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, etc. For more information, please visit the company websites www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to comply with the non-liability safe harbor requirements of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our plans, goals, statements and controversies and are not historical facts, and are usually made by using such things as “may”, “should”, “may”, “expect”, “plan”, “anticipate” "," "believe", "estimate", "forecast" and other terms to identify, "potential", "continue" and similar words, although some forward-looking statements are expressed in different ways. You should be aware that the forward-looking statements in this press release represent management’s current judgments and expectations, but our actual results, events and performance may differ materially from those in the forward-looking statements. Factors that may cause or contribute to such discrepancies include, but are not limited to, the risks discussed in our annual report on Form 10-K filed with the US Securities and Exchange Commission on March 9, 2021, and are based on the risks reported in our quarterly report. It is updated in Form 10-Q, as well as our press releases and other communications to shareholders from time to time, which attempt to provide stakeholders with risks and factors that may affect our business. We remind you not to rely too much on any such forward-looking statements. We assume no obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or other reasons, except as required by federal securities laws.
Please click to follow us on Facebook and Twitter
Investor Relations Contact: Terri Anne Powers, Vice President, Investor Relations and Corporate Communications (732) 482-9984 [email protected]
US Public Relations Contact: Eric Kim Rubenstein Public Relations 212-805-3052 [email protected]
More news releases on similar topics
Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time